An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304
Latest Information Update: 13 Sep 2024
At a glance
- Drugs Everolimus (Primary)
- Indications Epilepsy; Tuberous sclerosis
- Focus Adverse reactions; Registrational
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 12 Sep 2024 This trial has been completed in Hungary.
- 09 May 2023 Planned End Date changed from 4 Aug 2027 to 13 Aug 2027.
- 17 Jun 2022 This trial has been completed in Belgium, according to European Clinical Trials Database record.